沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究

黄英; 李艳; 刘恩梅; 陈坤华; 李芙蓉

doi:10.13406/j.cnki.cyxb.2005.01.040

您当前的位置：

首页 >

文章列表页 >

沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究

更新时间：2024-01-17

- 沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究
- Clinical study of salmeterol/fluticasone propionate combination in therapy of moderate to severe asthma in children
- 重庆医科大学学报 2005年第1期页码：132-135
- 作者机构：
  
  1. 重庆医科大学儿科学院呼吸科
  2. 重庆医科大学儿科学院呼吸科,重庆,400014
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.2005.01.040
  中图分类号： R725.6
- 纸质出版日期：2005，
扫描看全文
[1]黄英,李艳,刘恩梅,陈坤华,李芙蓉.沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究[J].重庆医科大学学报,2005(01):132-135.

HUANG Ying, et al. Clinical study of salmeterol/fluticasone propionate combination in therapy of moderate to severe asthma in children[J]. Journal of Chongqing Medical University, 2005,(1):132-135.
[1]黄英,李艳,刘恩梅,陈坤华,李芙蓉.沙美特罗替卡松联合治疗儿童中重度哮喘的临床研究[J].重庆医科大学学报,2005(01):132-135. DOI： 10.13406/j.cnki.cyxb.2005.01.040.

HUANG Ying, et al. Clinical study of salmeterol/fluticasone propionate combination in therapy of moderate to severe asthma in children[J]. Journal of Chongqing Medical University, 2005,(1):132-135. DOI： 10.13406/j.cnki.cyxb.2005.01.040.

摘要

目的观察吸入沙美特罗替卡松干粉剂6个月联合防治中、重度儿童哮喘的疗效和安全性。方法4～14岁中、重度哮喘患儿145例

按病情轻重分别给予沙美特罗替卡松

中度组50/100μg2吸/日

重度组50/100μg3吸/日

疗程6个月。记录治疗前、后2周、1月、2月、4月、6月时的临床症状评分、清晨呼气峰流速（PEFam）、使用缓解药物情况及不良反应。结果145例患儿的临床症状评分、PEFam在治疗后2周、1月、2月、4月、6月与治疗前比较均有显著改善（P<0.001）

不良反应发生率仅1.4%。结论沙美特罗替卡松联合防治儿童中、重度哮喘

能有效改善患儿PEFam及临床症状

临床应用安全。

Abstract

Objective:To investigate the efficacy and safety of 6 months inhalation of(SM/FP) among children.with moderate to severe asthma.Methods:145 children with moderate-severe asthma

aged between 4 and 14 years

were given SM/FP at the dose of 50/100μg twice daily in moderate group and 50/100μg 3 times every day in severe group for 6 months.The PEFam

symptom scores and the as-needed beta2 agonists were recorded at the beginning

2 weeks

1 month

2 months

4 months and 6 months after treatment.And the side effects were recorded also during the therapy.Results:Outcomes of clinical symptoms

PEFam and as-needed beta2 agomsts in all 145 cases improved significantly since 2 week ( P <0.001) after treatment and maintained throughout the therapy in the two groups.There was a very significant difference between the baseline and post-treatment ( P <0.001).The percentage suffering from side effects was 1.4%.Conclusion:SM/FP is an effective and safe medication for moderate-severe asthma in children.It could improve the PEFam and clinical symptoms obviously and rapidly.

关键词

沙美特罗替卡松儿童哮喘肺功能临床研究

Keywords

Salmeterol/fluticasone propionateAsthma in childrenlung functionclinical study

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

机器人辅助单边双通道内镜行腰椎减压融合内固定术的回顾性研究

咳嗽变异性哮喘免疫实验检测与临床防治观察

早期呼吸训练对冠脉搭桥术后患者肺功能恢复的效果评价

多塞平辅助治疗支气管哮喘的临床观察

重组人Elafin对慢性高氧诱导新生小鼠支气管肺发育不良中炎性因子及NF-κB信号通路的影响